FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004641340> ?p ?o ?g. }

• W2004641340 endingPage "51" @default.
• W2004641340 startingPage "34" @default.
• W2004641340 abstract "Backgrounds : 1. The acetylsalicylic acid (ASA, Aspirin) is very frequently used in the every day medical practice as platelet aggregation, analgetic, antipyretic agent in patients with myocardial infarction, prevention of stroke, different thrombophylic events and in different groups of patients and healthy subjects, however, it produces frequently serious gastrointestinal mucosal damage (bleeding, ulceration and perforation); 2. The gastrointestinal mucosal protection was proved by capsaicin(oids), when it (those) was (were) orally given in the doses, which are able to stimulate the capsaicin-sensitive afferent nerve fibers in animal experiments and human observations. Aims of this study were: 1. To evaluate the different pharmacokinetic parameters of capsaicin(oids) (given in doses in stimulatory doses of capsaicin-sensitive afferent nerves) in healthy male volunteers; 2. To study the action of capsaicin(oids) on the co-administration of ASA pharmacokinetic parameters and some pharmacological effect of ASA on the epinephrine-induced platelet aggregation, and 3. To follow strictly the internationally and the human clinical pharmacologically accepted pathway of the pharmaceutical production of a new drug combination [ASA + capsaicin(oids)] for the human medical therapy. Materials and Methods . 1. Fifteen human healthy male subjects were included into this human classical clinical pharmacological phase I., 2. The observations were carried out according to the “Protocol of Study” (protocol number: 1.4.1; EudraCT number: 2000-007048-32), which was permitted by the Hungarian Institute of Pharmacy (dated by June 4, 2009) and by the Hungarian Ethics of Committee for Clinical Pharmacology, Hungarian Medical Research Council (dated by March 1, 2009); 3. The criteria of inclusion and exclusion of healthy male subjects for this study were very strictly identified, 4. The screening and collection of the healthy males were maximally 2 weeks before the starting of study. 5. The phase I. examination covers 5 different sequences (7 days in each), and one week was the post study period, 6. The time-table of examinations (including a short hospitalization time, 3 days for washout, post-study examinations, food and fluid intakes, etc.) were determined, 7. The schedule of the administration of drugs [ASA alone, ASA + capsaicin(oids) – given orally in doses of 400 and 800µg, or placebo] was fixed by the protocol, 8. The human healthy male subjects were randomly treated, 9. The blood samples were obtained from the brachial vena (pre-dose, 0.10, 0.20, 0.40 1.00, 1.30, 2, 4, 6, 10, 12, 16 and 24 hours post dose), 10. The capsaicin and dihydrocapsaicin measured by HPLC, ASA and salicylic acid by HPLC from the plasma of healthy volunteers (during the first 24 hours period) and 11. The effects of capsaicinoids alone, ASA alone, and their combinations were studied on the epinephrine-induced platelet aggregation, 12. Different pharmacokinetic parameters ( C max , T max , AUC 0-tlast , AUC 0- ∞ , mean residence time, MRT ) of ASA and salicylic acid were calculated and these results and were compared in treated groups [ASA alone vs . ASA plus capsaicin(oids) 400 µg vs . ASA plus capsaicin(oids) 800 µg], 12. The extents of platelet aggregation produced by ASA alone and in different combination with capsaicin(oids) on the epinephrine-induced platelet aggregation. Results : 1. The healthy male volunteers tolerated well the different drug candidate combinations, and their applications were safe, 2. Neither capsaicin nor dihydrocapsaicin could be detected in any samples of plasma volunteers after oral application of capsaicin(oids) (given orally in doses of 400 µg and 800 µg) in time period of 0 to 24 hours; 3. The pharmacokinetic parameters of ASA and salicylic acid did not differ in groups treated with ASA alone vs . ASA plus 400 µg capsaicin(oids) vs . ASA plus 800 µg capsaicin(oids), 4. The capsaicin(oids) does (do) not modify the epinephrine-induced platelet aggregation induced by ASA, meanwhile the different doses of capsaicin(oids) alone have no direct effect of the epinephrine-induce platelet aggregation. Conclusions : 1. The capsaicin(oids) acts(act) locally in the gastrointestinal tract (indicating that we used a good selection of bioadhesive compounds for pharmaceutical preparation of ASA + capsaicin(iods) combination, 2. The results of these phase I. examinations offer us a further possibility to carry out forthcoming phase II. and III. examinations in patients." @default.
• W2004641340 created "2016-06-24" @default.
• W2004641340 creator A5015343495 @default.
• W2004641340 creator A5018911817 @default.
• W2004641340 creator A5021136235 @default.
• W2004641340 creator A5030763737 @default.
• W2004641340 creator A5051123483 @default.
• W2004641340 creator A5057168793 @default.
• W2004641340 creator A5075203847 @default.
• W2004641340 creator A5079050175 @default.
• W2004641340 date "2014-03-01" @default.
• W2004641340 modified "2023-09-27" @default.
• W2004641340 title "Orally Given Capsaicinoids do not Modify the Absorption, Metabolism, and Excretion of Aspirin and its Platelet Aggregation in Human Male Healthy Subjects (Human Clinical Pharmacological Phase. I. Examinations)" @default.
• W2004641340 cites W135382435 @default.
• W2004641340 cites W146873572 @default.
• W2004641340 cites W1481570004 @default.
• W2004641340 cites W1496803494 @default.
• W2004641340 cites W1511198581 @default.
• W2004641340 cites W1513314587 @default.
• W2004641340 cites W1527790940 @default.
• W2004641340 cites W1903416688 @default.
• W2004641340 cites W1959299100 @default.
• W2004641340 cites W1981816788 @default.
• W2004641340 cites W1988365789 @default.
• W2004641340 cites W1989847039 @default.
• W2004641340 cites W1990730118 @default.
• W2004641340 cites W1993540051 @default.
• W2004641340 cites W1999624824 @default.
• W2004641340 cites W2000284400 @default.
• W2004641340 cites W2012214760 @default.
• W2004641340 cites W2013735648 @default.
• W2004641340 cites W2014862507 @default.
• W2004641340 cites W2016326896 @default.
• W2004641340 cites W2017818343 @default.
• W2004641340 cites W2026738743 @default.
• W2004641340 cites W2032239683 @default.
• W2004641340 cites W2050792388 @default.
• W2004641340 cites W2058454285 @default.
• W2004641340 cites W2063710566 @default.
• W2004641340 cites W2069644133 @default.
• W2004641340 cites W2089053296 @default.
• W2004641340 cites W2111512333 @default.
• W2004641340 cites W2117459641 @default.
• W2004641340 cites W2125441842 @default.
• W2004641340 cites W2130549133 @default.
• W2004641340 cites W2130600650 @default.
• W2004641340 cites W2136486607 @default.
• W2004641340 cites W2138545090 @default.
• W2004641340 cites W2152874341 @default.
• W2004641340 cites W2166950143 @default.
• W2004641340 cites W2167067204 @default.
• W2004641340 cites W2413387718 @default.
• W2004641340 cites W2418229467 @default.
• W2004641340 cites W2500328495 @default.
• W2004641340 doi "https://doi.org/10.14205/2312-3710.2014.01.01.4" @default.
• W2004641340 hasPublicationYear "2014" @default.
• W2004641340 type Work @default.
• W2004641340 sameAs 2004641340 @default.
• W2004641340 citedByCount "0" @default.
• W2004641340 crossrefType "journal-article" @default.
• W2004641340 hasAuthorship W2004641340A5015343495 @default.
• W2004641340 hasAuthorship W2004641340A5018911817 @default.
• W2004641340 hasAuthorship W2004641340A5021136235 @default.
• W2004641340 hasAuthorship W2004641340A5030763737 @default.
• W2004641340 hasAuthorship W2004641340A5051123483 @default.
• W2004641340 hasAuthorship W2004641340A5057168793 @default.
• W2004641340 hasAuthorship W2004641340A5075203847 @default.
• W2004641340 hasAuthorship W2004641340A5079050175 @default.
• W2004641340 hasConcept C10146269 @default.
• W2004641340 hasConcept C121332964 @default.
• W2004641340 hasConcept C125287762 @default.
• W2004641340 hasConcept C126322002 @default.
• W2004641340 hasConcept C134018914 @default.
• W2004641340 hasConcept C185592680 @default.
• W2004641340 hasConcept C24890656 @default.
• W2004641340 hasConcept C2777628954 @default.
• W2004641340 hasConcept C2993802102 @default.
• W2004641340 hasConcept C62231903 @default.
• W2004641340 hasConcept C71924100 @default.
• W2004641340 hasConcept C89560881 @default.
• W2004641340 hasConcept C98274493 @default.
• W2004641340 hasConceptScore W2004641340C10146269 @default.
• W2004641340 hasConceptScore W2004641340C121332964 @default.
• W2004641340 hasConceptScore W2004641340C125287762 @default.
• W2004641340 hasConceptScore W2004641340C126322002 @default.
• W2004641340 hasConceptScore W2004641340C134018914 @default.
• W2004641340 hasConceptScore W2004641340C185592680 @default.
• W2004641340 hasConceptScore W2004641340C24890656 @default.
• W2004641340 hasConceptScore W2004641340C2777628954 @default.
• W2004641340 hasConceptScore W2004641340C2993802102 @default.
• W2004641340 hasConceptScore W2004641340C62231903 @default.
• W2004641340 hasConceptScore W2004641340C71924100 @default.
• W2004641340 hasConceptScore W2004641340C89560881 @default.
• W2004641340 hasConceptScore W2004641340C98274493 @default.
• W2004641340 hasIssue "1" @default.
• W2004641340 hasLocation W20046413401 @default.
• W2004641340 hasOpenAccess W2004641340 @default.
• W2004641340 hasPrimaryLocation W20046413401 @default.

• next